Flu Vaccine and Morbidity and Mortality in Dialysis PatientsFlu Vaccine and Morbidity and Mortality in Dialysis Patients
End-stage renal disease patients on peritoneal dialysis who received a flu vaccine realized a lower risk of morbidities and mortality than those who were non-vaccinated. Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 24, 2016 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news
Baxter launches trial for Vivia home hemodialysis system
Baxter (NYSE:BAX) said today that it’s launching a clinical trial of the Vivia home hemodialysis device it’s co-developing with famed inventor Dean Kamen’s DEKA Research & Development Corp.
The Vivia system is designed to provide shorter but more frequent dialysis rounds than conventional dialysis. The device has already won CE Mark approval in the European Union for use with Baxter’s Sharesource remote monitoring system, the company said.
Deerfield, Ill.-based Baxter said the 20-patient efficacystudy is designed to evaluate the Vivia system for frequent, extended nocturnal dialysis at home ...
Source: Mass Device - March 15, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Dialysis Baxter International Renal Source Type: news
NxStage touts home hemodialysis studies
NxStage Medical (NSDQ:NXTM) today touted data from studies of its Nx2me connected health technology and home hemodialysis systems, which the company plans to present at the 2016 Annual Dialysis Conference in Seattle later this month.
In a study of 328 patients treated with the company’s HHD using its Nx2me platform, NxStage reported a 44% reduction in controllable dropout when compared against patients not treated with the telehealth system.
The Nx2me Connected Health technology is a system focused through the Nx2me app that leverages tablets, cloud computing and wireless communications to collect home hemodialysis d...
Source: Mass Device - February 24, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Blood Management Clinical Trials Dialysis NxStage Medical Inc. Source Type: news
Attenuation of Peritoneal Fibrosis by Interleukin-10Attenuation of Peritoneal Fibrosis by Interleukin-10
Might immunomodulation with interleukin-10 offer an effective therapeutic strategy for prevention or treatment of peritoneal fibrosis, a complication of peritoneal dialysis? Laboratory Investigation (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 18, 2016 Category: Pathology Tags: Nephrology Journal Article Source Type: news
NxStage slumps despite Q1, FY2015 beats
NxStage saw shares plummet after releasing earnings that barely squeaked by Street expectations for their 4th quarter and full fiscal year 2015.
The Lawrence, Mass.-based company reported losses of $2.8 million, or 4¢ per share, on sales of $89.8 million for the 3 months ended December 31. That amounts to a 43.7% reduction in losses for the company as sales grew 12.4% compared with the same period in 2014.
Analysts on Wall Street were looking for losses per share of 4¢, right on target with the reported losses, and revenues of $86.8 million, which the company beat.
For the year, NxStage reported losses of $14.6 million, ...
Source: Mass Device - February 10, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup NxStage Medical Inc. Source Type: news
US FDA prioritizes devices requiring human factors reviews
By Stewart Eisenhart, Emergo Group
US medical device regulators have specified types of devices for which premarket application submissions should include human factors testing information, according to new Food and Drug Administration guidance.
The FDA guidance explains that devices it identifies warrant human factors data because of “clear potential for serious harm resulting from use error.” Such data is necessary for proper evaluation of safety, effectiveness and substantial equivalence, states the agency.
Premarket applications for the following device types should include human factors testing reports unless app...
Source: Mass Device - February 8, 2016 Category: Medical Equipment Authors: MassDevice Tags: Blog Emergo Group Source Type: news
What Factors Influence Linear Growth After Transplantation?
Discussion
Growth is a defining characteristic of children. Children are expected to have normal height, weight and head circumference growth velocities for their specific age. A review of mid-parental height determination and other growth parameters can be found here.
For children with chronic illness and organ dysfunction or failure, their bodies cannot be expected to continue to have normal growth and therefore these children often have failure of normal growth for any and all of the growth parameters. For children facing organ failure or high risk or relapsed cancers, organ transplantation can be life-saving, but is n...
Source: PediatricEducation.org - February 8, 2016 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Peritoneal Dialysis Solutions (Updated - Currently in Shortage)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 20, 2016 Category: Drugs & Pharmacology Source Type: news
Peritoneal Dialysis Solutions for Automated Peritoneal Dialysis (APD) therapy (Dianeal and Extraneal) (Updated - Currently in Shortage)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - January 19, 2016 Category: Drugs & Pharmacology Source Type: news
Geriatric assessment, falls and rehabilitation in patients starting or established on peritoneal dialysis - Jassal SV.
Individuals aged over 70 years at the time of starting dialysis have a varied and often challenging existence on dialysis. Canadian data suggest those starting dialysis between the ages of 75 and 79 years will have an average life expectancy of 3.2 years, ... (Source: SafetyLit)
Source: SafetyLit - January 11, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news
Rat Models of Acute and/or Chronic Peritoneal Injuries Including Peritoneal Fibrosis and Peritoneal Dialysis Complications
We describe herein two rat models of peritoneal injury that we have recently proposed. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 22, 2015 Category: Molecular Biology Source Type: news
Isolation and Propagation of Rat Peritoneal Mesothelial Cells
With the development of peritoneal dialysis in many countries, there has been much interest in the cell biology of peritoneal mesothelial cells. In this chapter we describe a reliable and reproducible method for the culture of rat primary mesothelial cells (RPMCs). This chapter outlines how to isolate mesothelial cells from rat peritoneum. The subculture of primary peritoneal mesothelial cells and the characterization by immunofluorescence is also described in detail. (Source: Springer protocols feed by Molecular Medicine)
Source: Springer protocols feed by Molecular Medicine - December 22, 2015 Category: Molecular Biology Source Type: news
Equivalent fall risk in elderly patients on hemodialysis and peritoneal dialysis - Farragher J, Rajan T, Chiu E, Ulutas O, Tomlinson G, Cook WL, Jassal SV.
Background: Accidental falls are common in the hemodialysis (HD) population. The high fall rate has been attributed to a combination of aging, kidney disease-related morbidity, and HD treatment-related hazards. We hypothesized that patients maintained on p... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - December 11, 2015 Category: Global & Universal Tags: Age: Elder Adults Source Type: news
Debiotech, Fresenius partner to develop home dialysis tech
Swiss med device firm Debiotech and dialysis device developer Fresenius Medical said today they are partnering to develop home-usable peritoneal dialysis technologies.
The companies said they aim to create a platform of dialysis machines that are lightweight and compact to allow patients to travel with the device and use them at home.
The newly partnered companies added that they intended to develop an easy-to-pickup set of instructions for the devices to make them easier to adopt for new users.
“This agreement represents an ideal synergy to help patients everywhere who suffer from end stage renal disease receive th...
Source: Mass Device - November 3, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Dialysis Research & Development Debiotech Fresenius Medical Care Source Type: news
